In order to maintain its dominance in the obesity field, Novo Nordisk has signed a strategic partnership with Flagship Pioneering startup, Metaphore Biotechnologies, to develop novel treatment approaches for cardiometabolic and rare diseases. Through the deal, which is worth up to US$600 M, the companies will utilise Metaphore's MIMIC platform to develop up to two multitarget therapeutics leveraging GLP-1R and related biology for obesity management. The agreement marks the third deal signed under the broader strategic partnership between Novo and Flagship announced in May 2022.